echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PLoS patch: new engineering peptides may show potential long-term anti HIV potential

    PLoS patch: new engineering peptides may show potential long-term anti HIV potential

    • Last Update: 2019-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    December 9, 2019 / Biovalley BIOON / -- recently, in a research report published in the international journal PLoS patterns, scientists from Fudan University and other institutions found that a new engineering peptide ibp-cp24 may be a long-term anti HIV drug, which can be used alone or with a wide range of neutralizing antibodies to treat and prevent HIV-1 infection Photo source: Bi W, et al (2019) in this study, the researchers pointed out that ibp-cp24 can show a long half-life, and also can potentially carry anti HIV-1 activity widely, even for drug-resistant strains Enflucetin is the first anti HIV peptide drug approved by FDA However, due to its short half-life and easy to produce drug-resistant HIV strains, the clinical application of enflucetin is often limited In this study, the researchers developed a new strategy, which can extend the half-life of the peptide by fusing the anti HIV short peptide named Cp24 onto the human immunoglobulin G (IgG) Fc binding peptide (IBP) Ibp-cp24 can inhibit broad-spectrum HIV-1 strains, including those resistant to enfluviride; more importantly, its half-life in macaque blood can reach 46.1 hours, which is nearly 26 and 14 times of that of Cp24 and enfluviride; intravenous injection of ibp-cp24 in macaque does not induce significant specific antibody response to ibp-cp24, and does not show significant toxic effect The mice that received ibp-cp24 in advance were also immune from HIV-1 infection, while the mice that received ibp-cp24 and normal human IgG at the same time could significantly reduce the virus content in their blood What's more, the combination of ibp-cp24 and broad-spectrum HIV neutralizing antibody can show a synergistic anti-HIV-1 effect, which shows that this strategy can help reduce the dosage of antibody and peptide, and also reduce the cost of treatment Original source: Wenwen Bi, Wei Xu, Liang Cheng, et al IgG Fc binding motif converged HIV-1 fusion initiator exists improved potential and in vivo life: potential app app lication in combination with broad neutralizing antibodies PLoS patchog 2019,15 (12): e1008082 Doi: 10.1371/journal.ppat.1008082
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.